• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Respir J . COVID-19 infection and its impact on case-fatality in patients with pulmonary embolism

tetano

Editor, Senior Moderator
Eur Respir J


. 2022 Aug 18;2200619.
doi: 10.1183/13993003.00619-2022. Online ahead of print.
COVID-19 infection and its impact on case-fatality in patients with pulmonary embolism


Lukas Hobohm[SUP] 1 2 3 [/SUP], Ingo Sagoschen[SUP] 4 3 [/SUP], Stefano Barco[SUP] 2 5 [/SUP], Ioannis T Farmakis[SUP] 2 6 [/SUP], Ugo Fedeli[SUP] 7 [/SUP], Sebastian Koelmel[SUP] 8 [/SUP], Tommaso Gori[SUP] 4 [/SUP], Christine Espinola-Klein[SUP] 4 [/SUP], Thomas Münzel[SUP] 4 9 [/SUP], Stavros Konstantinides[SUP] 2 10 [/SUP], Karsten Keller[SUP] 4 2 11 [/SUP]



Affiliations

Abstract

Background: Although a high prevalence of pulmonary embolism (PE) has been reported in association with coronavirus disease (COVID)-19 in critically ill patients, nationwide data on the outcome of hospitalised patients with COVID-19 and PE is still limited. Thus, we investigated seasonal trends and predictors of in-hospital death in patients with COVID-19 and PE in Germany.
Methods: We used the German nationwide inpatient sample to analyse data on hospitalisations among COVID-19 patients with and without PE during 2020, and to detect changes in PE prevalence and case fatality in comparison to 2019.
Results: We analysed 176,137 COVID-19 hospitalisations in 2020; PE was recorded in 1.9% (n=3362) of discharge certificates. Almost one third of patients with COVID-19 and PE died during the in-hospital course (28.7%) compared to COVID-19 patients without PE (17.7%). Between 2019 and 2020, numbers of PE-related hospitalisations were largely unchanged (98,485 versus 97,718), whereas the case-fatality rate of PE increased slightly in 2020 (from 12.7% to 13.1%, p<0.001). Differences in case fatality were found between PE patients with and without COVID-19 in 2020 (28.7% versus 12.5%, p<0.001), corresponding to a 3.1-fold increased risk of PE-related death (OR 3.16, 95% CI 2.91-3.42, p<0.001) in the presence of COVID-19.
Conclusions: In Germany, the prevalence of PE events during hospitalisations was similar in 2019 and 2020. However, the fatality rate among patients with both COVID-19 and PE was substantially higher than that in those with only one of these diseases, suggesting a life-threatening additive prognostic impact of the COVID-PE combination.
 
Back
Top Bottom